RT Journal Article
T1 Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants
A1 García Pérez, Javier
A1 Portolés Pérez, Antonio
A1 Pérez Ingidua, Carla
A1 Lora Pablos, David
A1 Gómez De La Cámara, Agustín Ramón
A1 Díez Fuertes, Francisco
A1 Ascaso del Río, Ana
AB SummaryCombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).
PB Elsevier
SN 2589-0042
YR 2024
FD 2024-09-20
LK https://hdl.handle.net/20.500.14352/116260
UL https://hdl.handle.net/20.500.14352/116260
LA eng
NO García-Pérez J, Borobia AM, Pérez-Olmeda M, Portoles A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JM, López A, Ascaso-del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J Carcas AJ, Díez-Fuertes F, * and CombiVacS Study Group. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants. iScience. 2024 Sep; 27;9:110728. ISSN 2589-0042. https://doi.org/10.1016/j.isci.2024.110728.
NO Instituto de Salud Carlos III (España)
DS Docta Complutense
RD 4 abr 2025